Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
3 hedge funds and large institutions have $24.9M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less capital invested
Capital invested by funds: $27.2M → $24.9M (-$2.31M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$7.64M |
| 2 |
IUHSA
Itau Unibanco Holding S.A.
Sao Paulo,
Brazil
|
+$3.05K |
Top Sellers
BHVN Hedge Fund Activity: Q2 2024 in Review
3 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q2 2024, worth a combined $24.9M — down 8.5% from $27.2M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BHVN positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Knoll Capital Management, adding an estimated $7.64M.
- 3 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q2 2024, up from 2 in Q1 2024.
- Funds reported $24.9M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q2 2024, down 8.5% quarter-over-quarter.
- 1 fund opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q2 2024 and 0 closed out, a net change of +1 holder.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q2 2024 was Knoll Capital Management, an estimated $7.64M added.
Based on aggregated 13F filings for Q2 2024.